Allgenesis Biotherapeutics Inc. Company Profile
Background
Founded in 2014 and headquartered in Taipei, Taiwan, Allgenesis Biotherapeutics Inc. is a privately held, clinical-stage biopharmaceutical company specializing in the development of innovative ophthalmic therapies. The company's mission is to address unmet medical needs in eye diseases through the creation of novel treatments. Allgenesis focuses on developing multi-specific fusion proteins and small molecule eye drops targeting conditions such as diabetic macular edema (DME), wet age-related macular degeneration (nAMD), dry eye disease (DED), and pterygium.
Key Strategic Focus
Allgenesis's strategic objectives center on advancing its pipeline of ophthalmic drugs to provide effective and durable treatment options for patients. The company specializes in:
- Multi-Specific Fusion Proteins: Developing bi-functional molecules that simultaneously target multiple pathways involved in retinal diseases.
- Small Molecule Eye Drops: Creating topical formulations for anterior segment eye diseases.
By leveraging these technologies, Allgenesis aims to address both anti-VEGF responders and non-responders, offering comprehensive solutions for complex ocular conditions.
Financials and Funding
As of 2024, Allgenesis Biotherapeutics reported annual revenue of approximately $5.5 million and employed nine individuals. The company has secured multiple funding rounds, including a later-stage venture capital investment of $4.15 million in September 2019. Notable investors include Axil Capital Partners, China Investment & Development, H&Q Asia Pacific, and Formosa Laboratories. The capital raised is primarily allocated to advancing clinical trials and expanding the company's therapeutic pipeline.
Pipeline Development
Allgenesis's pipeline features several promising candidates:
- AG-73305: A bi-specific Fc-fusion protein targeting VEGF and integrins for the treatment of DME, nAMD, and retinal vein occlusion (RVO). Preliminary Phase 2a data presented at the 2023 American Academy of Ophthalmology conference demonstrated safety and efficacy, with a mean improvement in Best Corrected Visual Acuity (BCVA) of +6.4 ETDRS letters and a central subfield thickness (CST) reduction of -100 microns at four weeks post-injection. The effects lasted up to 24 weeks after a single injection.
- AG-80308: A formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop for DED. Phase 1b results indicated safety and improvements in both signs and symptoms of DED, with plans to initiate a Phase 2 trial in the first quarter of 2024.
- AG-86893: A small molecule tyrosine kinase inhibitor eye drop targeting pterygium and associated hyperemia. Phase 2 trials have been conducted in Australia, focusing on safety and efficacy in treating these conditions.
Technological Platform and Innovation
Allgenesis distinguishes itself through its proprietary technologies and scientific methodologies:
- Bi-Specific Fusion Proteins: AG-73305 exemplifies this approach by concurrently inhibiting VEGF and integrin pathways, addressing multiple mechanisms involved in retinal diseases.
- Small Molecule Formulations: AG-80308 and AG-86893 represent innovative applications of small molecules in ophthalmic conditions, offering non-invasive treatment options.
The company's commitment to innovation is further evidenced by its robust patent portfolio, including patents for fusion proteins inhibiting angiogenesis and ophthalmic formulations of tyrosine kinase inhibitors.
Leadership Team
Allgenesis's leadership comprises experienced professionals:
- Dr. Chih-Ming Chen: Founder and Chairman, providing strategic direction and oversight.
- Dr. Madhu Cherukury: Chief Executive Officer, leading the company's operations and strategic initiatives.
- Dr. Sunil Patel: Chief Medical Officer, overseeing clinical development and medical affairs.
Competitor Profile
Market Insights and Dynamics
The ophthalmic pharmaceutical market is experiencing significant growth, driven by an aging population and increasing prevalence of eye diseases. Innovations in biologics and targeted therapies are shaping the competitive landscape.
Competitor Analysis
Key competitors include:
- Regeneron Pharmaceuticals: Developer of Eylea, a leading anti-VEGF therapy for retinal diseases.
- Novartis: Producer of Beovu, another anti-VEGF treatment for nAMD.
- Ocular Therapeutix: Focuses on sustained-release therapies for ocular conditions.
These companies have established products and extensive pipelines, contributing to a dynamic and competitive market environment.
Strategic Collaborations and Partnerships
In September 2021, Allgenesis entered into a licensing agreement with AffaMed Therapeutics for the development and commercialization of AG-73305 in Greater China, South Korea, and multiple ASEAN markets. This partnership aims to leverage AffaMed's regional expertise to accelerate AG-73305's development and market entry.
Operational Insights
Allgenesis's strategic considerations include:
- Differentiation: Focusing on multi-target therapies to address complex mechanisms in eye diseases.
- Market Positioning: Targeting both anti-VEGF responders and non-responders to capture a broader patient population.
- Innovation: Investing in proprietary technologies to develop first-in-class treatments.
Strategic Opportunities and Future Directions
Allgenesis is poised to:
- Advance Clinical Programs: Progress AG-73305 and AG-80308 through subsequent clinical trial phases.
- Expand Partnerships: Seek additional collaborations to enhance development capabilities and market reach.
- Innovate: Continue developing novel therapies to address unmet needs in ophthalmology.
Contact Information
- Website: Allgenesis Biotherapeutics Inc.
- LinkedIn: Allgenesis Biotherapeutics Inc.
Allgenesis Biotherapeutics Inc. remains dedicated to transforming the treatment landscape for eye diseases through innovative research and development.
